Peptides DB
Research-centric peptide and protocol reference hub
Study 10 of 13Tesofensine literatureMovement disorders clinical practice · Observational2026

Risk of Falls and Need of Walking Aid in Parkinson's Disease: Incidence and Impact of Comorbidities.

Falls and the need for walking aids are common in Parkinson's disease, with modifiable risk factors providing potential targets for intervention.

Read at Movement disorders clinical practiceAdd to compare

Where it sits

this study against the rest of the tesofensine corpus
6
Preclinical
6
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

The study investigated the incidence of falls and the need for walking aids in 415 Parkinson's disease patients over a 10-year period. It identified cognitive decline, freezing, and comorbidities like diabetes and depression as risk factors for falls. Older age and lower walking speed were associated with increased walking aid use.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
66.5% experienced falls 10 years after diagnosis.n=4152026

Abstract

The authors’ words, as Movement disorders clinical practice supplied them

<h4>Background</h4>Predicting falls in patients with Parkinson's disease (PD) is challenging despite their significant frequency and consequences.<h4>Objectives</h4>To determine incidences of first fall, walking aid requirement, and identify risk factors of subsequent risk, including factors unrelated to PD.<h4>Methods</h4>Study in 415 PD patients (DIGPD prospective cohort). Cumulative incidence curves were calculated and Generalized Linear Mixed Models investigated influencing factors.<h4>Results</h4>Five years after diagnosis, 26.1% of patients experienced falls while only 2.1% required walking aids; after 10 years, it rose to 66.5% and 17%, respectively. Median time to first fall was 7.9 years. Risk factors of falls were cognitive decline, freezing, comorbidities such as diabetes and depression, history of falls particularly in male, or low Body Mass Index (BMIs). Walking aids risk factors were older age, freezing, lower walking speed, higher BMIs, history of walking aid.<h4>Conclusions</h4>Treatable comorbidities (depression, diabetes, weight regulation) should be addressed in daily care to avoid falls in PD patients.

Background

Falls are a common and serious issue for patients with Parkinson's disease (PD), often leading to significant morbidity. Predicting and preventing falls in this population is challenging due to the complex interplay of disease-related and unrelated factors. This study aims to quantify the incidence of falls and walking aid use in PD patients and to identify modifiable risk factors, which could inform clinical management strategies.

Methods

The study was conducted using a prospective cohort design involving 415 patients with Parkinson's disease from the DIGPD cohort. Cumulative incidence curves were used to determine the incidence of falls and walking aid use over time. Generalized Linear Mixed Models were employed to identify risk factors influencing these outcomes. The primary outcomes were the incidence of first falls and the requirement for walking aids over a 10-year period.

Results

Five years post-diagnosis, 26.1% of patients experienced falls, and 2.1% required walking aids. By 10 years, these figures increased to 66.5% and 17%, respectively. The median time to the first fall was 7.9 years. Risk factors for falls included cognitive decline, freezing, comorbidities such as diabetes and depression, a history of falls, male gender, and low BMI. Risk factors for requiring walking aids included older age, freezing, lower walking speed, higher BMI, and a history of walking aid use.

Interpretation

The study highlights that a significant proportion of PD patients experience falls and require walking aids over time. The identified risk factors, many of which are modifiable, suggest potential targets for intervention to reduce fall risk. However, the observational nature of the study limits causal inference, and the findings may not be generalizable beyond the studied cohort. The clinical significance of these findings lies in the potential for targeted management of comorbidities to mitigate fall risk.

Key findings

  • 26.1% of patients experienced falls 5 years after diagnosis.
  • 2.1% required walking aids 5 years after diagnosis.
  • 66.5% experienced falls 10 years after diagnosis.
  • 17% required walking aids 10 years after diagnosis.
  • Median time to first fall was 7.9 years.

Limitations

  • observational study design
  • specific to DIGPD cohort
  • potential for unmeasured confounding
  • findings may not generalize to all PD populations

Elsewhere in the Tesofensine corpus

CPlasma membrane transporters Alp1 and Nrt1 mediate the uptake of benzamidine conjugates in fungi.Cell surface (Amsterdam, Netherlands) · 2026In vitroCChronic High-Fat Diet Does Not Alter Overall Cancer Incidence in Trp53R270H/+ Mice.Cancer research communications · 2026 · n=359 · No significant effect on overall survival or tumor burden in Trp53R270H/+ mice after more than 1 year of HFD.AnimalDUltrasensitive Chemical Detection Using Integrating Cavity-Enhanced Raman Spectroscopy.Analytical chemistry · 2026 · Peak average reflectivity of 99.943 ± 0.0004% at 610 nm.reviewBThe Long-Term Impact of Adolescent Community Weapon-Related Violence Exposure on Depression: Insomnia as a Mediating Pathway.Journal of community psychology · 2026 · n=3924 · Insomnia accounted for 7% of the total effect of weapon-related violence on depressive symptoms.HumanCThe WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads.iScience · 2026 · Not reported in abstract.AnimalBEpidemiology and severity of pediatric influenza hospitalizations before and during the COVID-19 pandemic: a surveillance study of the Canadian immunization monitoring program (IMPACT), 2012-2023.Lancet regional health. Americas · 2026 · n=10091 · Odds of severe disease lower in 2021-2022 (aOR 0.63, 95% CI 0.44-0.89) and 2022-2023 (aOR 0.85, 95% CI 0.74-0.98) compared to pre-pandemic.Human